SCHEMBL18944071

SCHEMBL18944071

O=c1ccc2ccc(CCCO)cc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 2/20 0.49
▸ PDE3A Q14432 2/20 0.49
▸ P2RY12 Q9H244 2/20 0.49
▸ HTR1A P08908 11/20 0.43
▸ DRD2 P14416 8/20 0.43
▸ HTR2A P28223 8/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA3 P07451 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ CA5A P35218 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CA13 Q8N1Q1 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ CA5B Q9Y2D0 1/20 0.43
▸ SLC6A4 P31645 4/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18944234 0.95 PDE3B (0.49) PDE3BPDE3AP2RY12HTR1ADRD2
SCHEMBL18944067 0.90 CA12 (0.46) HTR1ADRD2HTR2ACA12CA1
SCHEMBL18932524 0.83 GPR84 (0.47) PDE3BPDE3AHTR1ADRD2HTR2A
SCHEMBL3064748 0.82 CA12 (0.48) PDE3BPDE3AHTR1ADRD2HTR2A
SCHEMBL18932519 0.82 GPR84 (0.47) HTR1ADRD2HTR2ACA12CA1
SCHEMBL18932514 0.81 GPR84 (0.47) HTR1ADRD2HTR2ASLC6A4
SCHEMBL18932511 0.79 CA12 (0.46) PDE3BPDE3AHTR1ADRD2HTR2A
SCHEMBL31377064 0.75 PARP1 (0.48) HTR1ADRD2HTR2ACA12CA1
SCHEMBL764285 0.75 DAO (0.60) PDE3BPDE3ACA12CA1CA3
SCHEMBL1438379 0.75 CA12 (0.48) PDE3BPDE3AHTR1ADRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174011-B2 Heterocyclic compounds, process for preparation of the same and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-01-08 — — US disclosed
US-20170158680-A1 HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174011-B2 Heterocyclic compounds, process for preparation of the same and use thereof CYP11B2, CYP11B1, ADCYAP1R1 PDE3B 534/4885PDE3A 474/4885P2RY12 1731/4885
US-20170158680-A1 HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF CYP11B2, CYP11B1, ADCYAP1R1 PDE3B 534/4885PDE3A 474/4885P2RY12 1731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback